

LAW OFFICES OF LEONA L. LAUDER

INTELLECTUAL PROPERTY - SPECIALIZING IN BIOTECHNOLOGICAL AND CHEMICAL PATENTS
235 MONTGOMERY STREET, SUITE 1026
SAN FRANCISCO, CALIFORNIA 94104-3008
TELEPHONE (415) 981-2034 FAX (415) 981-0332

RECEIVED
CENTRAL FAX CENTER

NOV 13 2006

FACSIMILE MESSAGE

TO : Examiner Brandon J. Fetterolf, PhD.
Group Art Unit 1642 FAX NO.: 571-273-8300

FROM: Leona L. Lauder DATE : November 13, 2006

NO. OF PAGES FOLLOWING: 30

IMPORTANT NOTICE

The information contained in this facsimile message may include attorney-client privileged and confidential information intended only for the use of the individual or entity named above and others who have been specifically authorized to receive it. If you are not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone (415-981-2034) and return the original transmission to us by mail without making a copy. Thank you.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Claudiu Supuran et al.

Serial No.: 10/723,795

Group Art Unit: 1642

Filed : November 26, 2003

Examiner: B.J. Fetterolf

For : CA IX-Specific Inhibitors

Certificate of Facsimile Transmission

I hereby certify that this paper and the documents referred to as attached therein are being facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

November 13, 2006
Date

Denise Ortega
Name

RECEIVED
CENTRAL FAX CENTER

NOV 13 2006

Denise Ortega
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Claudiu Supuran et al.

Serial No.: 10/723,795

Group Art Unit: 1642

Filed : November 26, 2003

Examiner: B.J. Fetterolf

For : CA IX-Specific Inhibitors

AMENDMENT TRANSMITTAL

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is a response to the Office Action comprising a Restriction Requirement mailed from the U.S. Patent and Trademark Office (PTO) on October 12, 2006 with a one-month shortened statutory period for response.

No additional fee should be required for the accompanying Amendment. The fee for the claims has been calculated as shown below:


	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	18	MINUS	69	0	X \$ 50	\$ 0.00
INDEP.	4	MINUS	7	0	X \$ 200	\$ 0.00

[] FIRST PRESENTATION OF MULTIPLE DEP. CLAIM + \$360 \$ 0.00

TOTAL \$ 0.00

However, should any additional fees be determined to be necessary in connection with this paper, Applicants respectfully request that any such additional fees be charged to Deposit Account No. 12-0615.

Respectfully submitted,


Leona L. Lauder
Attorney for Applicants
Registration No. 30,863

Dated: November 13, 2006

Certification of Facsimile Transmission

I hereby certify that this paper and the documents referred to as attached therein are being facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

November 13, 2006
Date

Denise Ortega
Name

RECEIVED
CENTRAL FAX CENTER

NOV 13 2006

Signature

Denise Ortega

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Claudiu Supuran et al.

Serial No. : 10/723,795

Group Art Unit: 1642

Filed : November 26, 2003

Examiner: B. J. Fetterolf, PhD.

For : CA IX-Specific Inhibitors

RESPONSE TO RESTRICTION REQUIREMENT AND
PRELIMINARY AMENDMENT

MAIL STOP PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper is in response to the Office Action comprising a Restriction Requirement concerning the above-identified application, which Office Action was mailed from the U.S. Patent and Trademark Office (PTO) on October 12, 2006 with a

one month shortened statutory period for response, and signed by Examiner Brandon J. Fetterolf, PhD. and his Supervisory Patent Examiner (SPE) Jeffery Siew.¹

RECEIVED
CENTRAL FAX CENTER

NOV 13 2006

Response to Restriction Requirement – Group VII Election

Applicants respectfully traverse the 7-way Restriction Requirement but elect the Group VII Claims 67-69 “drawn to a method of imaging tumors and/or metastases that express CA IX in a patient comprising administering a CA IX-specific inhibitor linked to a imaging agent. . . .” [Office Action, page 3.] Applicants in making that election cancel Claims 1-66 but reserve the right under 35 USC Section 121 to file subsequent divisional applications to protect the invention commensurate with the scope as originally filed.

Preliminary Amendment

Preliminary to the examination of the above-identified Group VII Claims 67-69, Applicants respectfully request that the subject application be amended to add new Claims 70-84. New Claims 70-84 point out with more particularity and clarity the subject matter of the Group VII claims “drawn to a method of imaging tumors and/or metastases that express CA IX in a patient comprising administering a CA IX-specific inhibitor linked to an imaging agent. . . .” [Office Action, page 3.]

1. Applicants respectfully point out that a second Restriction Requirement that is substantively different but whose cover sheet indicates that it was from Examiner Fetterolf's office, was mailed from the PTO on the same day to the Applicants. The second Restriction Requirement was signed by Examiner Erich A. Leeser and his SPE James O. Wilson. Applicants contacted Examiner Leeser about the two different Restriction Requirements for the subject application. Examiner Leeser, after consultation with his SPE, called the undersigned Attorney for the Applicants to inform the Applicants that the Restriction Requirement signed by him and his SPE would be withdrawn.